# Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

> **NCT07325214** · NA · NOT_YET_RECRUITING · sponsor: **IMGT Co., Ltd.** · enrollment: 136 (estimated)

## Conditions studied

- Pancreatic Cancer
- Borderline Resectable Pancreatic Cancer
- Locally Advanced Pancreatic Cancer

## Interventions

- **DEVICE:** IMD10
- **DRUG:** chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]

## Key facts

- **NCT ID:** NCT07325214
- **Lead sponsor:** IMGT Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07325214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07325214, "Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07325214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*